One of India's leading pharmaceutical companies, Piramal Life Sciences has announced that it has started the phase-II study into its upcoming diabetic drug.
The company's Managing Director Somesh Sharma revealed that the phase-II study of 'P1736-05' has been started and the company was confident of a successful completion of the study.
Advertisement
The P1736-05 is an insulin sensitizing compound which will be a part of the company's new drug for the treatment of type-2 diabetes in India and Europe.
"The commencement of phase-II trial of P1736-05 in India and Europe speaks of our efforts to build a diversified and strong pipeline of products to address unmet medical needs. P1736-05 is likely to provide a safe and effective therapeutic option to type-2 diabetic patients", Sharma added.
Source: Medindia
Source: Medindia
Diabetes and Exercise
Regular exercise especially in type II diabetes not only helps reduce the sugar but also reduces the demand for medication by 20% and helps you stay healthy.
Advertisement
 Diabetic Diet Insulin : Sugar and FoodEncyclopedia section of medindia briefly explains about Insulin - Sugar and Food | Advertisement
|
Advertisement
Recommended Reading
Latest Clinical Trials News
Researchers tested the effectiveness of virus-mediated gene therapy for genetic hearing loss in an aged mouse model with genetic changes related to deafness.
The outcomes of the first clinical trial demonstrate the safety and efficacy of the measles-rubella (MR) vaccination to adults and infants as young as 9 months.
Scientists devise a fully integrated autonomous wearable ultrasonic-system-on-patch to sense deep tissue vital signs wirelessly even when the patient is on the move.
Combination of chemotherapy drugs was found to show promising results in patients with pancreatic cancer.
A new clinical trial is testing the safety, tolerability, and processing in the body of drug product HOPO 14-1 that removes radioactive contamination in healthy adults.